KR102078444B1 - 1-((2r,4r)-2-(1h-벤조[d]이미다졸-2-일)-1-메틸피페리딘-4-일)-3-(4-시아노페닐)우레아 말레에이트의 결정질 형태 - Google Patents

1-((2r,4r)-2-(1h-벤조[d]이미다졸-2-일)-1-메틸피페리딘-4-일)-3-(4-시아노페닐)우레아 말레에이트의 결정질 형태 Download PDF

Info

Publication number
KR102078444B1
KR102078444B1 KR1020177030098A KR20177030098A KR102078444B1 KR 102078444 B1 KR102078444 B1 KR 102078444B1 KR 1020177030098 A KR1020177030098 A KR 1020177030098A KR 20177030098 A KR20177030098 A KR 20177030098A KR 102078444 B1 KR102078444 B1 KR 102078444B1
Authority
KR
South Korea
Prior art keywords
ppm
crystalline form
glassdecib
maleate
values
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177030098A
Other languages
English (en)
Korean (ko)
Other versions
KR20170129245A (ko
Inventor
에릭 크리스티안 한센
크리스토퍼 스콧 시딕
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102078444(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20170129245A publication Critical patent/KR20170129245A/ko
Application granted granted Critical
Publication of KR102078444B1 publication Critical patent/KR102078444B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020177030098A 2015-04-24 2016-04-13 1-((2r,4r)-2-(1h-벤조[d]이미다졸-2-일)-1-메틸피페리딘-4-일)-3-(4-시아노페닐)우레아 말레에이트의 결정질 형태 Active KR102078444B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562152108P 2015-04-24 2015-04-24
US62/152,108 2015-04-24
PCT/IB2016/052107 WO2016170451A1 (en) 2015-04-24 2016-04-13 Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197009092A Division KR20190038677A (ko) 2015-04-24 2016-04-13 1-((2r,4r)-2-(1h-벤조[d]이미다졸-2-일)-1-메틸피페리딘-4-일)-3-(4-시아노페닐)우레아 말레에이트의 결정질 형태

Publications (2)

Publication Number Publication Date
KR20170129245A KR20170129245A (ko) 2017-11-24
KR102078444B1 true KR102078444B1 (ko) 2020-02-17

Family

ID=55806563

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177030098A Active KR102078444B1 (ko) 2015-04-24 2016-04-13 1-((2r,4r)-2-(1h-벤조[d]이미다졸-2-일)-1-메틸피페리딘-4-일)-3-(4-시아노페닐)우레아 말레에이트의 결정질 형태
KR1020197009092A Withdrawn KR20190038677A (ko) 2015-04-24 2016-04-13 1-((2r,4r)-2-(1h-벤조[d]이미다졸-2-일)-1-메틸피페리딘-4-일)-3-(4-시아노페닐)우레아 말레에이트의 결정질 형태

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197009092A Withdrawn KR20190038677A (ko) 2015-04-24 2016-04-13 1-((2r,4r)-2-(1h-벤조[d]이미다졸-2-일)-1-메틸피페리딘-4-일)-3-(4-시아노페닐)우레아 말레에이트의 결정질 형태

Country Status (24)

Country Link
US (4) US10414748B2 (https=)
EP (2) EP3666768B1 (https=)
JP (1) JP6345728B2 (https=)
KR (2) KR102078444B1 (https=)
CN (1) CN107531667A (https=)
AR (1) AR104391A1 (https=)
AU (1) AU2016251940C1 (https=)
BR (1) BR112017021075B1 (https=)
CA (2) CA2983387C (https=)
CY (2) CY1124056T1 (https=)
DK (2) DK3286176T3 (https=)
ES (2) ES2923593T3 (https=)
HK (1) HK1243416A1 (https=)
HU (2) HUE059506T2 (https=)
IL (1) IL255224B (https=)
MX (1) MX375384B (https=)
PL (2) PL3286176T3 (https=)
PT (2) PT3286176T (https=)
RU (1) RU2717564C2 (https=)
SG (1) SG11201707863QA (https=)
SI (2) SI3286176T1 (https=)
TW (1) TWI646093B (https=)
WO (1) WO2016170451A1 (https=)
ZA (1) ZA201706391B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414748B2 (en) 2015-04-24 2019-09-17 Pfizer Inc. Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
HRP20240302T1 (hr) 2020-01-28 2024-05-10 Assia Chemical Industries Ltd Postupci za pripremu glasdegiba i njegove soli i krutih oblika glasdegib maleata i postupak za njihovu pripremu
EP4126237B1 (en) 2020-03-26 2024-04-10 LEK Pharmaceuticals d.d. Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy
WO2023017541A1 (en) * 2021-08-12 2023-02-16 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methyl piperidin-4-yl)-3-(4-cyanophenyl)urea maleate
CN114668849B (zh) * 2021-12-31 2024-01-23 中国人民解放军军事科学院军事医学研究院 Shh通路调控生物节律及其相关应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090005416A1 (en) * 2007-06-29 2009-01-01 Pfizer Inc. Benzimidazole derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2008001575A1 (fr) 2006-06-28 2008-01-03 Nikon Corporation Dispositif de localisation, dispositif de mise au point automatique et appareil photographique
US10414748B2 (en) * 2015-04-24 2019-09-17 Pfizer Inc. Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090005416A1 (en) * 2007-06-29 2009-01-01 Pfizer Inc. Benzimidazole derivatives

Also Published As

Publication number Publication date
CA2927736A1 (en) 2016-10-24
AU2016251940A1 (en) 2017-10-12
IL255224A0 (en) 2017-12-31
AR104391A1 (es) 2017-07-19
HUE048664T2 (hu) 2020-07-28
RU2717564C2 (ru) 2020-03-24
US20180086731A1 (en) 2018-03-29
SI3666768T1 (sl) 2022-09-30
CY1124056T1 (el) 2022-03-24
EP3666768A1 (en) 2020-06-17
RU2017137269A3 (https=) 2019-09-13
US20220024894A1 (en) 2022-01-27
ES2774053T3 (es) 2020-07-16
TWI646093B (zh) 2019-01-01
TW201702238A (zh) 2017-01-16
AU2016251940B2 (en) 2018-08-30
KR20190038677A (ko) 2019-04-08
US20190382368A1 (en) 2019-12-19
BR112017021075B1 (pt) 2021-08-03
EP3286176B1 (en) 2020-01-15
PT3286176T (pt) 2020-02-24
CA2983387C (en) 2022-08-16
SG11201707863QA (en) 2017-11-29
PL3286176T3 (pl) 2020-11-30
DK3666768T3 (da) 2022-06-27
EP3286176A1 (en) 2018-02-28
JP6345728B2 (ja) 2018-06-20
US11168066B2 (en) 2021-11-09
CA2983387A1 (en) 2016-10-27
BR112017021075A2 (pt) 2018-07-03
MX375384B (es) 2025-03-06
EP3666768B1 (en) 2022-06-15
RU2017137269A (ru) 2019-05-24
PL3666768T3 (pl) 2022-09-19
ZA201706391B (en) 2020-12-23
JP2016204373A (ja) 2016-12-08
PT3666768T (pt) 2022-07-22
HUE059506T2 (hu) 2022-11-28
SI3286176T1 (sl) 2020-04-30
WO2016170451A1 (en) 2016-10-27
DK3286176T3 (da) 2020-03-02
IL255224B (en) 2021-01-31
ES2923593T3 (es) 2022-09-28
MX2017013645A (es) 2018-03-08
US11891372B2 (en) 2024-02-06
US10414748B2 (en) 2019-09-17
US20220024893A1 (en) 2022-01-27
CY1125333T1 (el) 2025-03-28
NZ735719A (en) 2020-11-27
US11891373B2 (en) 2024-02-06
AU2016251940C1 (en) 2019-04-11
CN107531667A (zh) 2018-01-02
KR20170129245A (ko) 2017-11-24
HK1243416A1 (zh) 2018-07-13

Similar Documents

Publication Publication Date Title
US11891372B2 (en) Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
US10689380B1 (en) Crystalline forms of valbenazine ditosylate
US11149017B2 (en) Solid state forms of apalutamide
JP2018502140A (ja) ベンズイミダゾール誘導体の新規結晶形及びその製造方法
EP3022209B1 (en) Dolutegravir potassium salt
EP3016954B1 (en) Crystalline forms of ponatinib hydrochloride
JP6148412B1 (ja) アピキサバンの合成の重要な中間体及び不純物：アピキサバングリコールエステル
KR102858471B1 (ko) Lta4h 저해제의 결정질 형태
KR20190064589A (ko) 4-(2-((1r,2r)-2-히드록시시클로헥실아미노)벤조티아졸-6-일옥시)-n-메틸피콜린아미드의 결정질 형태
NZ735719B2 (en) Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
US20250257054A1 (en) Salt forms of a 4h-pyran-4-one structured cyp11 a1 inhibitor
JP2020535192A (ja) レナリドミドの結晶形
EA029298B1 (ru) Полиморфные формы n-карбамоилметил-4(r)-фенил-2-пирролидона

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20171019

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181022

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181022

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190328

PJ0201 Trial against decision of rejection

Patent event date: 20190328

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20190128

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20191224

Appeal identifier: 2019101001061

Request date: 20190328

J301 Trial decision

Free format text: TRIAL NUMBER: 2019101001061; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20190328

Effective date: 20191224

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20191224

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20190328

Decision date: 20191224

Appeal identifier: 2019101001061

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20200120

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20191226

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200211

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200211

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20221221

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240102

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20241223

Start annual number: 6

End annual number: 6